Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Date:3/19/2013

CRANBURY, N.J., March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914 (the '914 application).  The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides.

Palatin is conducting in vitro and animal in vivo studies with the peptides claimed in the allowed patent and with related peptides.  Proposed indications under study include dermatologic indications such as vitiligo and erythropoietic protoporphyria, inflammatory bowel disease, ocular indications such as uveitis and dry eye, and nephritis and other kidney conditions.  Palatin plans to designate an initial clinical lead peptide candidate in the first half of 2013 and start toxicology and other preclinical studies preparatory to filing an Investigational New Drug Application with the U.S. Food and Drug Administration.

The peptides claimed in the '914 application are highly specific for the melanocortin-1 receptor, with sub-nanomolar affinity binding and EC50 functional values.  The peptides are also highly selective for the melanocortin-1 receptor, with greater than one thousand times the affinity for the melanocortin-1 receptor than for the melanocortin-4 or melanocortin-3 receptors.

"We are excited by the potential of our novel melanocortin receptor-1 peptides," stated Carl Spana , Ph.D., President and CEO of Palatin. "There are a number of significant unmet medical needs for which our highly specific and selective peptides can potentially provide new therapies."

'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Patient Safety Technologies Reports Fourth Quarter And Fiscal 2012 Results
3. Medbox Acquires 50% of MedVend and its Patented Technologies
4. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
5. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
6. Xyntek-Antares & ESS Technologies to Unveil New Ultra Compact TaskMate(R) Robotic Case Erector / Loader with Track & Trace at Interphex 2013
7. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
8. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
11. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... BETHESDA, Md. , Sept. 19, 2014 ... an initiative to harmonize global post-approval changes protocols. ... level of interest in the topic expressed by industry participants ... workshop, held earlier this month in Washington, ... and EMA were on hand for the workshop. Attendees ...
(Date:9/19/2014)... Sept. 19, 2014 Kiromic, LLC, a ... Kent Hance , the former chancellor of Texas Tech ... as chancellor in July 2014, after raising $1.2 billion for ... Kent Hance , the most successful chancellor in the ... not only as an investor, but also as our new ...
(Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... ALISO VIEJO, Calif., Nov. 9 Clarient, Inc. (Nasdaq: ... oncologists and the pharmaceutical industry, today announced that it is ... New York City. , The first presentation will be made ... 1:40 pm EST on Tuesday, November 17. The conference will ...
... Care Reform Bill , Critical legislation would strengthen ... Nov. 7 Today the United States House ... strengthen Medicare for seniors and end discrimination by insurance companies ... , The Affordable Health Care for America Act ...
Cached Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2AARP Idaho Key Vote News Alert 2AARP Idaho Key Vote News Alert 3
(Date:9/19/2014)... structure could help predict how willing you are to take ... University found those with greater volume in a part of ... likely to engage in risky behavior than people with less ... the U.S. National Institute on Aging, involved two groups of ... researchers sought to determine how brain structure influences risk taking ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... By Alan Mozes ... (HealthDay News) -- Cancer patients burdened by stress and ... for complications following their operation, a new study suggests. ... "deficit" appeared to have a nearly three times greater ... or good quality of life. "We,ve long known ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
(Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
Breaking Medicine News(10 mins):Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:A better way to track emerging cell therapies using MRIs 2
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... antigen (PSA) levels are rising rapidly over time are of ... be done, a new study indicates. PSA is a ... of PSA can be a marker for prostate cancer, although ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, Feb. ... plague will probably remain a scourge of centuries past, isolated ... fact, according to a just-released government report, a American lab ... of plague from a laboratory-acquired infection since 1959 and the ...
... , THURSDAY, Feb. 24 (HealthDay News) -- ... risk of cancer due to high radiation doses, and ... radiation exposure, a new study suggests. The researchers ... dialysis also have other health conditions that require them ...
... cancer organizations have recommended that men with a rapid rise ... there is no other indication and the PSA is within ... PSA velocityis a poor predictor of prostate cancer, and may ... online February 24 in the Journal of the National ...
... link between victimization experiences and substance abuse has been ... Chicago. The correlation is especially prevalent among gays, ... says Tonda Hughes, professor and interim head of health ... is lead author of the study, published in the ...
... THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart rapidly ... a day after birth, scientists report. With this discovery, ... be found to help the human heart heal itself. ... but they,re somehow permanently switched off," said Eric Olson, co-senior ...
Cached Medicine News:Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 2Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 3Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Strong link found between victimization, substance abuse 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of the ... up to 12 Criterion gels in a single ... x 8.7 cm) than the traditional mini gel. ... to give you the optimal combination of separation ...
... The PROTEAN Plus Dodeca cell accommodates ... the capacity of first-dimension runs in the ... in a convenient format. The PROTEAN Plus ... with its plate electrodes, allow consistent, high-resolution ...
... ElectroXpress gel electrophoresis system mirrors a 96-well ... screening of PCR products to take place ... source (96-well) plate. Loading can be carried out ... first time in the industry two sets ...
Medicine Products: